CALR and neoplasm: Patient samples were subdivided by disease stage, stage II and stage III, and the ratio of calreticulin (Fig. 2a), calnexin (Fig. 2b), GRP78 (Fig. 2c) and GRP94 (Fig. 2d) in tumour versus normal tissue was evaluated.